Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Baricitinib is a safe and effective treatment for severe alopecia areata.

This study found that curcumin lowered fasting blood sugar levels and improved menstruation characteristics in women with polycystic ovary syndrome, but it did not affect other metabolic, hormonal, or hirsutism indices.

This study found that magnesium supplementation significantly improved overall quality of life in women with polycystic ovary syndrome, but did not significantly affect acne, alopecia, or abnormal uterine bleeding.

In this randomized trial, the researchers observed that both montelukast and finasteride effectively reduced acne severity and lesion count in women with moderate acne, but finasteride showed greater efficacy. Both medications had transient, non-serious side effects, indicating satisfactory tolerability and safety.

This study found that oral zinc sulphate appeared effective and safe for treating thallium poisoning, particularly in reducing hair and skin symptoms and mitigating its severe progression in patients.

This study found that paclitaxel poliglumex showed limited effectiveness and was relatively well tolerated in post-menopausal women with advanced NSCLC, suggesting further testing of this treatment may not be justified.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

In this study of women with frontal fibrosing alopecia, delgocitinib cream improved the molecular signature of lesions and demonstrated potential as a treatment, showing significant transcriptomic changes and some clinical improvements over 12 weeks compared to a cream vehicle.

This study found that using Alastin Restorative Skin Complex Serum 2.0 with TriHex Technology for 12 weeks significantly improved facial skin hydration, elasticity, and overall quality in individuals with moderate to severe skin aging, with histological evidence showing new collagen and elastin fibers.

Most men prefer keeping their eyebrows over scalp hair.

This study found that injecting Platelet-Rich Plasma into the anastomotic line during low anterior resection for rectal cancer eliminated anastomotic leakage, reducing its incidence from 13.3% in the control group to 0% in the PRP group.

This study found that dutasteride improved maximum urinary flow rate more effectively than finasteride when used in combination therapy with tamsulosin for treating benign prostatic hyperplasia over six months.

This study found that topical calcipotriol was significantly more effective than topical tacrolimus in promoting hair growth for alopecia areata patients, demonstrating 67% efficacy compared to 33% efficacy with tacrolimus over a 6-month period.

This clinical trial found that topical rosuvastatin and melatonin creams significantly reduced the severity of mild to moderate plaque psoriasis over 12 weeks, with a satisfactory safety profile.

This study found that both methotrexate and azathioprine were equally effective and well-tolerated in improving symptoms of lichen planopilaris over six months, with no significant difference between the two treatments in terms of efficacy.

This study found that both 0.01% and 0.03% bimatoprost gel and 2% minoxidil gel significantly improved eyebrow density in individuals with hypotrichosis, with no significant difference between the treatments, although the highest bimatoprost concentration showed a more favorable response.

This study reported that Tomorrowlabs HIF strengthening factor [HSF] hair restoration technology significantly improved hair thickness, density, shine, and elasticity, while reducing hair loss by an average of 66.8% and enhancing hair growth by up to 32.5% in subjects with androgenic alopecia over nine months.

This study concluded that ALRV5XR treatment significantly increased terminal hair density in both men and women with androgenetic alopecia and telogen effluvium, with more pronounced effects in women.

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

This study evaluates the effectiveness and safety of 2-mg and 4-mg doses of baricitinib in patients with alopecia areata who have lost at least 50% of their scalp hair, comparing outcomes between those with early and late onset of the disease.

This study suggests that observing the acute telogen effluvium triad—frontal fringe, temporal recess, and occipital fringe—can aid in diagnosing telogen effluvium during resolution phases, despite challenges like negative pull tests.

In this study, adding topical calcipotriol 0.005% to topical clobetasol 0.05% significantly improved treatment efficacy for Alopecia Areata compared to using clobetasol alone, as evidenced by a greater reduction in SALT scores over 24 weeks.

This letter discusses the variability in platelet-rich plasma preparation for androgenetic alopecia treatment and highlights that different methods yield varied platelet concentrations but not significant differences in growth factor secretion per platelet.

This study found that reflexology massage significantly improved hair regrowth in women with chemotherapy-induced alopecia compared to those receiving usual care.

Topical treatment SM04554 safely promotes hair growth in male baldness.

Abatacept may help some people with alopecia areata regrow hair.

In this study, researchers found that retinoids might improve lupus nephritis resistant to conventional treatments, but the sample size was too small for significant results, and side effects were noted.

This study found that weekly low-dose bicalutamide was safe and appeared to be associated with high-grade PIN remission and favorable PSA modulation in subjects with persistently elevated PSA but negative biopsy.

This letter challenges an interpretation of results from a zinc lozenge trial that suggested patient perceptions of receiving treatment might indicate effective blinding, arguing this only holds for crossover studies.

In this study, Korean adults with damaged hair who took 3g/day of low-molecular-weight collagen peptide GT for 24 weeks showed significant improvements in hair gloss, elasticity, and scalp elasticity compared to placebo, without any adverse events.